Sangamo Therapeutics

Yahoo Finance • 21 days ago

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR st... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics Inc (NASDAQ:SGMO) Reports Q2 2025 Earnings: Revenue Misses but Narrower-Than-Expected Loss

Sangamo Therapeutics Inc (NASDAQ:SGMO [https://www.chartmill.com/stock/quote/SGMO]) reported its second-quarter 2025 financial results, missing revenue estimates but delivering a narrower-than-expected loss per share. The clinical-stage bi... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics, Inc. Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s top-line findings from its Phase 1/2 STAAR study, H.C. Wainwright reaffirmed its Buy rati... Full story

Yahoo Finance • 3 months ago

Sangamo stock holds Buy rating at H.C. Wainwright on Fabry therapy data

Investing.com - H.C. Wainwright reiterated its Buy rating and $10.00 price target on Sangamo BioSciences (NASDAQ:SGMO) following the company’s announcement of top-line results from its Phase 1/2 STAAR trial. Want deeper insights into biote... Full story

Yahoo Finance • 3 months ago

Sangamo rises after trial data for Fabry disease therapy

[Book with diagnosis Fabry disease and pills. Medical concept.] designer491 Shares of Sangamo Therapeutics (NASDAQ:SGMO [https://seekingalpha.com/symbol/SGMO]) traded higher in the premarket on Tuesday after the company announced positive... Full story

Yahoo Finance • 3 months ago

Sangamo reports positive results for Fabry disease gene therapy

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a clinical-stage biotechnology company with a market capitalization of $103 million and trailing twelve-month revenue of $64 million, announced positive topline results from its... Full story

Yahoo Finance • 4 months ago

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Upfront License Fee: Received $18 million from Eli Lilly for the first target under the STAC-BBB license agreement. Potential Milestone Payments: Eligible to earn up to $1.4 billion in additional license target fees and milestone payments... Full story

Yahoo Finance • 2 years ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participant... Full story

Yahoo Finance • 3 years ago

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

https://cdn.benzinga.com/files/images/story/2023/03/20/sgmo_logo_light__df15263084666d45f8f072d9581b42da.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Two big-name partners have walked away from partnerships with Sangamo Therapeutic... Full story

Yahoo Finance • 3 years ago

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

BRISBANE, Calif., April 28, 2022--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the mark... Full story